At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 26 enrolled
Drug / intervention
Oral Topotecandrug
Likely dose
Oral Topotecan 0.25mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Oral Topotecan, Utilization for a Metronomic Dosing Schedule to Treat Recurrent or Persistent Solid Tumors
Accelerated Community Oncology Research Network·interventional·Posted Sep 29, 2006·Updated Jul 22, 2013
In Brief
A Phase 2 clinical trial evaluating Oral Topotecan for Tumors. Completed, enrolled 26 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the effectiveness of oral topotecan and how well the chemotherapy is tolerated (any side effects) when it is given in different dose levels. The study will also collect information on how the medication is being broken down and absorbed in the body and how quality of life is affected during treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTumors
CountriesUnited States
CollaboratorsGlaxoSmithKline
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 2006
Enrollment StartNov 2006
Primary CompletionMar 2011
TodayJul 2026
First PostedSep 29, 2006
Enrollment StartNov 1, 2006
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 19.8 years ago
Interventions
Oral Topotecandrug
Topotecan will be received in one of the five dose levels:0.25mg/day,0.5mg/day, 0.75mg/day, 1.0mg/day, and 1.25mg/day.